BioMarin Pharmaceutical Inc. (BMRN) Meets Expectations But The Biggest Coming Catalyst is Likely to Only Offer Fleeting Revenue Bump
Tweet Send to a Friend
Nomura/Instinet analyst Christopher Marai reiterated a Neutral rating and $77.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
